Prescription Required
Formulation: Extended Release Capsule
(Brand Option)
Select the prescribed dosage
Select the quantity to see the price.
Prescription Required
Formulation: Extended Release Capsule
Select the quantity to see the price.
* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Rytary contains two active ingredients: carbidopa and levodopa. It is a prescription medication used to treat Parkinson’s disease and certain Parkinson-like movement symptoms.
Rytary is an extended-release capsule. This means it releases the medication gradually to help provide more consistent symptom control over several hours.
Parkinson’s disease is a progressive neurological condition that affects movement. It develops when the brain does not produce enough dopamine, a natural chemical that helps control smooth and coordinated movement.
Symptoms may include tremors, muscle stiffness, slowed movement, difficulty walking, poor balance, and problems with coordination. Some people may also experience periods when their symptoms return or become worse as a dose begins to wear off.
Rytary may help reduce these movement-related symptoms and improve the ability to complete everyday activities. It can also help manage “off” periods, when Parkinson’s symptoms return between doses.
Rytary helps control symptoms, but it does not cure Parkinson’s disease or stop the condition from progressing.
Levodopa is converted into dopamine after it enters the brain. This helps replace some of the dopamine that is missing in people with Parkinson’s disease.
Carbidopa prevents levodopa from being broken down too quickly before it reaches the brain. This allows more levodopa to reach the brain and also helps reduce certain side effects, such as nausea and vomiting.
Together, carbidopa and levodopa help improve dopamine activity in the brain. This may reduce tremors, stiffness, slowed movement, and difficulty with coordination.
Rytary contains both immediate-release and extended-release forms of carbidopa and levodopa. Part of the dose begins working relatively quickly, while the rest is released more gradually.
This extended-release design may help provide smoother symptom control and reduce the amount of time spent in an “off” state. However, the response varies from person to person, and the dose often needs to be adjusted carefully.
Rytary is not directly interchangeable with other carbidopa and levodopa products. A healthcare provider must calculate the appropriate dose when changing from another formulation.
Rytary is an extended-release capsule taken by mouth. It is often taken three times daily, but some people may take it up to five times daily when more frequent dosing is needed and tolerated. Follow the exact schedule prescribed by your healthcare provider and take each dose at approximately the same times every day.
Swallow each capsule whole. Do not chew, crush, divide, or break the capsule because doing so may interfere with the way the medication is gradually released.
If you have difficulty swallowing capsules, carefully twist the capsule apart and sprinkle all of its contents onto one or two tablespoons of applesauce.
Swallow the mixture immediately without chewing it. Do not store the mixture or prepare it in advance for a later dose.
Rytary may be taken with or without food. However, food can affect how quickly or completely levodopa is absorbed, so try to take it consistently in relation to meals.
A high-fat, high-calorie meal may delay the absorption of levodopa and the onset of the medication’s effects by approximately two to three hours. For this reason, you may be advised to take the first dose of the day about one to two hours before eating. Follow the meal-timing instructions provided by your healthcare provider.
A high-protein meal may reduce the absorption of levodopa in some people. You do not need to completely avoid protein, because it remains an important part of a balanced diet. However, your healthcare provider or dietitian may recommend separating Rytary from high-protein meals or adjusting when you eat most of your daily protein if food appears to interfere with symptom control.
Rytary doses are not directly interchangeable with other carbidopa and levodopa products. Do not take another medication containing carbidopa or levodopa unless your healthcare provider specifically instructs you to do so.
When changing from immediate-release carbidopa and levodopa to Rytary, your healthcare provider must calculate a new starting dose and adjust it according to your symptoms and side effects. The use of Rytary together with other levodopa products has not been adequately studied.
Your dosage is based on your previous levodopa treatment, Parkinson’s symptoms, response to Rytary, and any side effects you experience. Your healthcare provider will aim to use the lowest dose that provides adequate symptom control.
Do not increase, reduce, or suddenly stop Rytary without medical guidance. Suddenly stopping the medication or rapidly lowering the dose may cause a serious reaction involving fever, severe muscle stiffness, confusion, or changes in consciousness. The dose should normally be reduced gradually when treatment is discontinued.
Contact your healthcare provider or pharmacist if you are unsure about your dosing schedule, how to coordinate Rytary with meals, or how to take it with your other Parkinson’s medications.
Rytary (Carbidopa/Levodopa ER) is available in the following forms and strength:
Rytary may cause a sudden drop in blood pressure when you stand up after sitting or lying down. This is called orthostatic hypotension and may cause dizziness, lightheadedness, fainting, or falls.
The risk may be greater when you first begin treatment or after your dose is increased. Older adults may also be more vulnerable to falls. Stand up slowly and hold onto something stable until you know how the medication affects you.
Contact your healthcare provider if you frequently feel dizzy, faint, or unsteady.
Rytary may cause hallucinations, confusion, agitation, unusual dreams, or difficulty distinguishing what is real. Hallucinations may involve seeing, hearing, or feeling things that are not present.
These effects may be more likely shortly after treatment begins or after the dose is increased. Older adults and people with a history of certain psychiatric conditions may have a greater risk.
Tell your healthcare provider promptly about hallucinations, severe confusion, suspicious thoughts, agitation, aggressive behaviour, or other significant changes in thinking or behaviour. Rytary is generally not recommended for people with a major psychotic disorder because it may worsen psychosis.
Rytary may cause new involuntary movements or worsen movements that are already present. These uncontrolled movements are called dyskinesias and may affect the face, mouth, arms, legs, or other parts of the body.
Contact your healthcare provider if these movements become troublesome. Your Rytary dose or another Parkinson’s medication may need to be adjusted. Do not change the dose on your own.
Rytary may cause significant drowsiness. Some people taking medications containing levodopa have fallen asleep suddenly during everyday activities, sometimes without feeling sleepy beforehand.
Do not drive, operate machinery, or perform another potentially dangerous activity until you know how Rytary affects you. Tell your healthcare provider if you experience severe daytime sleepiness or suddenly fall asleep while eating, talking, driving, or completing another activity.
Alcohol and other medications that cause drowsiness may increase this risk.
Tell your healthcare provider and pharmacist about every prescription medication, over-the-counter product, vitamin, and supplement you take before starting Rytary.
Do not take Rytary with a nonselective monoamine oxidase inhibitor, also called an MAOI, or within two weeks after stopping one. Examples include phenelzine and tranylcypromine. Combining these medications may cause dangerously high blood pressure.
Certain selective MAO-B inhibitors used for Parkinson’s disease may sometimes be prescribed with Rytary, but the combination may increase the risk of low blood pressure when standing. Other medications, including dopamine-blocking antipsychotics, metoclopramide, and some iron supplements, may also affect how well Rytary works or how it is absorbed.
Do not begin, stop, or change another medication without first consulting your healthcare provider.
Before taking Rytary, tell your healthcare provider about all your medical conditions, particularly heart disease, irregular heart rhythms, glaucoma, a history of hallucinations or psychosis, sleep disorders, or a history of uncontrolled urges or compulsive behaviours.
Also mention any kidney or liver disease, although the effects of these conditions on Rytary have not been fully studied. A history of stomach ulcers, asthma, or another significant medical problem should be discussed so your healthcare provider can determine whether additional monitoring is appropriate.
People with Parkinson’s disease may experience changes in mood or behaviour, and Rytary can sometimes contribute to psychiatric symptoms. Anxiety has been reported during treatment, and suicidal thoughts or attempts have occurred in some patients.
Contact your healthcare provider immediately if you develop new or worsening depression, severe anxiety, suicidal thoughts, hallucinations, unusual behaviour, or major changes in mood.
Some people may also develop intense or uncontrollable urges, such as compulsive gambling, excessive shopping, binge eating, or increased sexual urges. The person taking Rytary may not recognize these changes, so family members and caregivers should also watch for them.
Rytary may cause urine, saliva, or sweat to become darker in colour. This effect is usually harmless, but it may stain clothing or bedding.
Tell your healthcare provider if the colour change occurs with other symptoms, such as painful urination, yellow skin or eyes, severe weakness, or abdominal pain, because these symptoms may have another cause.
Rytary may be taken with or without food. It does not have to be taken with food, although taking it with a small meal may help reduce nausea for some people.
A high-fat, high-calorie meal may delay the medication’s effect by approximately two to three hours. High-protein foods may also reduce levodopa absorption in some patients.
Try to take Rytary consistently in relation to meals and follow the meal-timing instructions provided by your healthcare provider. Do not completely eliminate protein from your diet unless a qualified healthcare professional advises you to do so.
Tell your healthcare provider if you have glaucoma or increased pressure inside your eyes. People with chronic wide-angle glaucoma may sometimes use Rytary if their eye pressure is well controlled, but regular monitoring may be needed.
Report eye pain, sudden blurred vision, severe headache, halos around lights, or redness of the eye immediately, as these symptoms require urgent medical attention.
Take Rytary exactly as prescribed. Do not increase, reduce, or suddenly stop the medication without medical guidance.
Contact your healthcare provider about persistent dizziness, fainting, severe sleepiness, uncontrolled movements, hallucinations, unusual urges, or significant changes in mood or behaviour. Seek urgent medical attention for chest pain, sudden loss of consciousness, suicidal thoughts, or a severe reaction involving fever, confusion, and extreme muscle stiffness.
Rytary is not necessarily better for everyone with Parkinson’s disease. The best medication depends on your symptoms, response to previous treatments, side effects, dosing needs, and daily routine. Rytary contains extended-release carbidopa and levodopa. It may be helpful for people who experience “off” periods, which are times when Parkinson’s symptoms return or worsen as a dose of medication wears off. In a clinical study involving people with advanced Parkinson’s disease, Rytary reduced daily “off” time more than immediate-release carbidopa and levodopa. It also increased “on” time without troublesome involuntary movements. However, individual results vary, and the dose usually needs to be adjusted carefully.
Yes. Rytary can cause new involuntary movements or make existing movements worse. These movements are called dyskinesias and may affect the face, mouth, arms, legs, or other parts of the body. Contact your healthcare provider if you develop new movements or if existing dyskinesias become more frequent or difficult to manage. Your Rytary dose or another Parkinson’s medication may need to be reduced. Do not change your dose without medical guidance.
Do not crush, chew, divide, or break Rytary capsules because this can interfere with the extended-release formulation. However, the capsule may be opened if you have difficulty swallowing it. Carefully twist the capsule apart and sprinkle all of its contents onto one or two tablespoons of applesauce. Swallow the mixture immediately without chewing it, and do not save it for later use.
Yes. Rytary may cause hallucinations or psychotic symptoms. Hallucinations may involve seeing, hearing, or feeling things that are not present. Other possible changes may include confusion, unusual dreams, agitation, suspicious thoughts, delusions, disorientation, or aggressive behaviour. These symptoms may occur soon after treatment begins and may improve if the levodopa dose is reduced under medical supervision. Tell your healthcare provider promptly if hallucinations or major changes in thinking or behaviour occur. Rytary is generally not recommended for people with a major psychotic disorder because it may worsen psychosis.
| Generic name: | Carbidopa/Levodopa ER |
|---|---|
| Formulation: | Extended Release Capsule |
| Strength(s): | 23.75/95mg, 36.25/145mg, 48.75/195mg |
| Quantities Available: | 100 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Rytary (carbidopa/levodopa ER) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is common for prescription medications to ensure adequate management of chronic conditions without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Rytary is available in various strengths of carbidopa/levodopa extended-release capsules, such as 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg.
For example, if you are prescribed Rytary 36.25 mg/145 mg and take 4 capsules per day: For a 90-day supply, you would order 360 capsules (90 days x 4 capsules per day).
No, our website does not sell carbidopa/levodopa ER directly. However, you can still enjoy low prices on Rytary, which contains carbidopa/levodopa as an active ingredient. To purchase Rytary, you will need a valid prescription from your healthcare provider. We require this to dispense the medication safely and legally. You can conveniently submit your prescription by mail, fax, or upload it through your online account to facilitate the ordering process.
Yes, we ship Rytary (carbidopa/levodopa ER) to both the United States and Puerto Rico.
Watch how Online Pharmacies Canada is helping customers save money on their medications.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Rytary (Carbidopa/Levodopa ER). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Rytary (Carbidopa/Levodopa ER).
REVIEWS